Past Communications
Experimental Dengue Vaccine Protects all Recipients in Human Trials
An experimental dengue vaccine, TV003 that was developed by Dr. Whitehead and his colleagues at NIAID’s Laboratory of Infectious Diseases along with scientists from the U.S. Food and Drug Administration Center for Biologics Evaluation and Research protected 100% of the vaccine recipients in a clinical trial. Volunteers in this trial Read more…